Skip to main content
ARS Home » Plains Area » Manhattan, Kansas » Center for Grain and Animal Health Research » ABADRU » Research » Research Project #425500

Research Project: Immunization of ABADRU Research Staff for Prevention of Rift Valley Fever

Location: Arthropod-borne Animal Diseases Research

Project Number: 3020-32000-009-19-T
Project Type: Trust Fund Cooperative Agreement

Start Date: Sep 1, 2013
End Date: Aug 31, 2018

ABADRU would like to request that the Kansas Research and Development Program fund the immunization of ABADRU staff members to prevent Rift valley fever (RVF) infections. Original plans were to immunize up to 11 staff members. However, increases in immunization costs, travel costs and program delays have caused ABADRU to re-evaluate the number of immunized staff that will be needed. Only four permanent full-time USDA ARS employees of ABADRU are now proposed for immunization (McVey, Ruder, Reister and Jasperson). All of these individuals have a significant effort (>60%) towards RVF research either through the USDA ARIS CRIS Project 5410-32000-004-00D, Countermeasures to Prevent, Mitigate, and Control Rift Valley Fever (RVF) or the KBA-funded project 5430-05-05 RVF Diagnostics and Vaccine Development and Evaluation. Both of these research projects are directed towards objectives of the NBAF mission as related to: (1) developing countermeasures for existing and emerging foreign animal disease threats; (2) providing advanced testing and evaluation capabilities for threat detection, vulnerability, and countermeasure assessment for animal and zoonotic diseases; (3) supporting licensure of vaccine countermeasures through essential animal model testing and evaluation; and (4) strengthening biosecurity education and training capabilities at K-State. All of the individuals listed (in addition to Drs. Wilson and Drolet who are already immunized) will have exposure to virulent, wild-type RVF virus. If these individuals are not immunized, the scope of the ABADRU mission and support of the NBAF mission would be significantly reduced.

Through USAMRIID: 1. Medical evaluation of selected ABADRU staff (4 individuals). 2. Complete immunization series of 4 doses of vaccine. 3. Serological determination of vaccine status after the series is completed.